NOVAVAX INC Deferred Revenue, Current
NOVAVAX INC (NVAX) had Deferred Revenue, Current of $1.26 billion as of 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2021-11-05
- 2021-09-30: Deferred Revenue, Current $1.26B.
- 2021-06-30: Deferred Revenue, Current $1.22B.
- 2021-03-31: Deferred Revenue, Current $822.81M.
- 2020-12-31: Deferred Revenue, Current $273.23M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2021-09-30 | $1.26B 10-Q · filed 2021-11-05 |
| 2021-06-30 | $1.22B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $822.81M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $273.23M 10-Q · filed 2021-11-05 |
| 2020-09-30 | $81.81M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $158.85M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.11M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.68M 10-K · filed 2021-03-01 |
| 2019-09-30 | $2.59M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $4.19M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $5.94M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $10.01M 10-K · filed 2020-03-11 |
| 2018-09-30 | $15.37M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $7.68M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $16.38M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $25.63M 10-K · filed 2019-03-18 |
| 2017-09-30 | $31.46M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $30.03M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $24.68M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $30.08M 10-K · filed 2018-03-14 |
| 2016-09-30 | $30.16M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $32.81M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $28.91M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $34.47M 10-K · filed 2017-02-27 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2014-09-30 | $3.00K 10-Q · filed 2014-11-06 |
| 2014-06-30 | $25.00K 10-Q · filed 2014-08-07 |
| 2014-03-31 | $57.00K 10-Q · filed 2014-05-08 |
| 2013-12-31 | $271.00K 10-Q · filed 2014-11-06 |
| 2013-09-30 | $190.00K 10-Q · filed 2013-11-12 |
| 2013-03-31 | $78.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $258.00K 10-K · filed 2014-03-12 |
| 2012-09-30 | $803.00K 10-Q · filed 2012-11-09 |
| 2011-06-30 | $2.50M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $0.00 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |